File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study

TitleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study
Authors
Phua, KBLim, FSLau, YLNelson, EASHuang, LMQuak, SHLee, BWTeoh, YLTang, HBoudville, IOostvogels, LCSuryakiran, PVSmolenov, IVHan, HHBock, HL
KeywordsDiarrhoea
Efficacy
Gastroenteritis
Human rotavirus vaccine
Rotavirus
Issue Date2009
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2009, v. 27 n. 43, p. 5936-5941 How to Cite?
DOI: http://dx.doi.org/10.1016/j.vaccine.2009.07.098
AbstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/170422
ISSN
0264-410X
2021 Impact Factor: 4.169
2020 SCImago Journal Rankings: 1.585
ISI Accession Number ID
WOS:000271170500004
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorPhua, KBen_US
dc.contributor.authorLim, FSen_US
dc.contributor.authorLau, YLen_US
dc.contributor.authorNelson, EASen_US
dc.contributor.authorHuang, LMen_US
dc.contributor.authorQuak, SHen_US
dc.contributor.authorLee, BWen_US
dc.contributor.authorTeoh, YLen_US
dc.contributor.authorTang, Hen_US
dc.contributor.authorBoudville, Ien_US
dc.contributor.authorOostvogels, LCen_US
dc.contributor.authorSuryakiran, PVen_US
dc.contributor.authorSmolenov, IVen_US
dc.contributor.authorHan, HHen_US
dc.contributor.authorBock, HLen_US
dc.date.accessioned2012-10-30T06:08:26Z-
dc.date.available2012-10-30T06:08:26Z-
dc.date.issued2009en_US
dc.identifier.citationVaccine, 2009, v. 27 n. 43, p. 5936-5941en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/170422-
dc.description.abstractThis study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subjectDiarrhoea-
dc.subjectEfficacy-
dc.subjectGastroenteritis-
dc.subjectHuman rotavirus vaccine-
dc.subjectRotavirus-
dc.subject.meshChild, Preschoolen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshGastroenteritis - Prevention & Control - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshRotavirus Infections - Prevention & Controlen_US
dc.subject.meshRotavirus Vaccines - Administration & Dosageen_US
dc.subject.meshVaccines, Attenuated - Administration & Dosageen_US
dc.titleSafety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2009.07.098en_US
dc.identifier.pmid19679216-
dc.identifier.scopuseid_2-s2.0-70349431081en_US
dc.identifier.hkuros170390-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70349431081&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue43en_US
dc.identifier.spage5936en_US
dc.identifier.epage5941en_US
dc.identifier.isiWOS:000271170500004-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridPhua, KB=7003538202en_US
dc.identifier.scopusauthoridLim, FS=7006112665en_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US
dc.identifier.scopusauthoridNelson, EAS=35071611500en_US
dc.identifier.scopusauthoridHuang, LM=7404736430en_US
dc.identifier.scopusauthoridQuak, SH=35512093800en_US
dc.identifier.scopusauthoridLee, BW=7405437980en_US
dc.identifier.scopusauthoridTeoh, YL=6603277028en_US
dc.identifier.scopusauthoridTang, H=15828580700en_US
dc.identifier.scopusauthoridBoudville, I=6507808395en_US
dc.identifier.scopusauthoridOostvogels, LC=34768573900en_US
dc.identifier.scopusauthoridSuryakiran, PV=26022588400en_US
dc.identifier.scopusauthoridSmolenov, IV=23499725700en_US
dc.identifier.scopusauthoridHan, HH=8545352800en_US
dc.identifier.scopusauthoridBock, HL=7201825902en_US
dc.identifier.citeulike5432708-
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats